Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY44.93 CNY
Change Today +2.12 / 4.95%
Volume 19.5M
600276 On Other Exchanges
As of 3:05 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

jiangsu hengrui medicine c-a (600276) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - CNY52.37
52 Week Low
07/31/14 - CNY25.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JIANGSU HENGRUI MEDICINE C-A (600276)

Related News

No related news articles were found.

jiangsu hengrui medicine c-a (600276) Related Businessweek News

No Related Businessweek News Found

jiangsu hengrui medicine c-a (600276) Details

Jiangsu Hengrui Medicine Co., Ltd. researches, manufactures, and sells pharmaceutical products in China. It offers antineoplastic, angiomyocardiac, antibiotic, and other drugs, as well as APIs in the form of tablets, injectables, injections, oral solutions, capsules, and ointments. The company was founded in 1970 and is headquartered in Lianyungang, China.

Founded in 1970

jiangsu hengrui medicine c-a (600276) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangsu hengrui medicine c-a (600276) Key Developments

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, Jul 13, 2015

Jiangsu Hengrui Medicine Co., Ltd., Board Meeting, Jul 13, 2015. Agenda: To discuss and approve issues including the proposal of 1st unlocking of some shares of equity incentive; to consider the proposal of establishing wholly-owned subsidiary in Suzhou; and to consider the proposal of increasing capital of subsidiary in Hong Kong.

Jiangsu Hengrui Medicine Co., Ltd. Announces Cash Dividend for 2014, Payable on June 15, 2015

Jiangsu Hengrui Medicine Co., Ltd. announced CNY 1.00 cash dividend per share (Tax included) and 2 bonus share and 1 share capitalized for every 10 shares. Cash payable on June 15, 2015 and record date on June 12, 2015. Ex-right and ex-dividend date on June 15, 2015.

MabSpace Biosciences Signs Collaborative Contract with Jiangsu Hengrui Medicine to Co-Develop Novel Antibody Therapeutics on Two Targets

MabSpace Biosciences has signed a collaborative contract with Jiangsu Hengrui Medicine to co-develop novel antibody therapeutics on two targets. Under the agreement, MabSpace will be responsible for the discovery and selection of humanised lead antibodies. Hengrui will receive exclusive global rights on any resulting therapeutic candidates and further develop the selected candidate molecules. The partnership is expected to leverage MabSpace's capabilities in in-vitro and in-vivo pharmacological profiling, as well as its experience in antibody discovery, alongside Hengrui's knowledge of process development, manufacturing, clinical development, and commercialisation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600276:CH CNY44.93 CNY +2.12

600276 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600276.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600276 Industry Range
Price/Earnings 49.8x
Price/Sales 10.5x
Price/Book 9.8x
Price/Cash Flow 50.0x
TEV/Sales 10.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGSU HENGRUI MEDICINE C-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at